Skip to main content

Table 1 Summary characteristics for the 21 eligible RCTs (10,187 patients)

From: Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis

Study Year Journal Ref Trial Number Study Design Treatment Patients (N) Male (%) Age (yr) Risk Group (%)
Sokal risk Hasford risk
low mid high low mid high
O’Brien (1) 2003 N Engl J Med [21,22,23] NCT
00006343
Phase III, randomized, open-label, multicenter (IRIS) Imatinib 400 mg qd 553 56.0 50(18–70) 53 29 18 46 44 10
IFN-α + Ara-C 553 61.0 51(18–70) 47 30 22 45 45 10
Cortes (1) 2009 J Clin Oncol [24] NCT
00124748
Phase III, randomized, multicenter Imatinib 800 mg qd 319 57.4 48(18–75) 42.3 34.8 23.0 / / /
Imatinib 400 mg qd 157 53.5 45(18–75) 39.5 33.8 27.0 / / /
Baccarani 2009 Blood [25] NCT
00514488
Randomized, multicenter Imatinib 800 mg qd 108 55.0 51(18–84) / / / / / /
Imatinib 400 mg qd 108 57.0 51(18–81) / / / / / /
Preudhomme 2010 N Engl J Med [26] NCT
00219739
Phase III, randomized (SPIRIT) Imatinib 400 mg qd 159 69.0 50 38 38 24 / / /
Imatinib 600 mg qd 160 56.0 51 37 38 28 / / /
Imatinib 400 mg qd + Ara-C 158 58.0 55 37 41 23 / / /
Imatinib 400 mg qd + IFN-α 160 65.0 51 36 40 24 / / /
Saglio 2010 N Engl J Med [27,28,29,30] NCT
00471497
Phase III, randomized, open-label, multinational, multicenter (ENESTnd) Nilotinib 300 mg bid 282 56.0 47(18–85) 37 36 28 / / /
Nilotinib 400 mg bid 281 62.0 47(18–81) 37 36 28 / / /
Imatinib 400 mg qd 283 56.0 46(18–80) 37 36 28 / / /
Kantarjian 2010 N Engl J Med [31,32,33,34,35] NCT
00481247
Phase III, randomized, multicenter (DASISION) Dasatinib 100 mg qd 259 56.0 46(18–84) / / / 33 48 19
Imatinib 400 mg qd 260 63.0 49(18–78) / / / 33 47 19
Petzer 2010 Haematologica [36] NCT
00327262
Randomized, multinational, multicenter (ISTAHIT) Imatinib 800 mg qd 113 46.5 46(18–76) / / / / / /
Imatinib 400 mg qd 113 42.5 46(20–68) / / / / / /
Cortes (2) 2011 Blood [37,38,39] NCT
00574873
Randomized, multinational, multicenter (BELA) Bosutinib 500 mg qd 250 60.0 48(19–91) 35 47 18 / / /
Imatinib 400 mg qd 252 54.0 47(18–89) 35 47 18 / / /
Hehlmann (1) 2011 J Clin Oncol [40] / Randomized, multinational, multicenter Imatinib 800 mg qd 338 59.0 52(18–86) / / / / / /
Imatinib 400 mg qd 325 60.0 64(16–88) / / / / / /
Imatinib 400 mg qd + IFN-α 351 61.0 54(16–83) / / / / / /
Radich 2012 Blood [41] NCT
00070499
Phase III, randomized, multinational, multicenter Dasatinib 100 mg qd 123 60.0 47(18–90) / / / 36 33 32
Imatinib 400 mg qd 123 59.0 50(19–89) / / / 36 37 28
Thielen 2013 Ann Hematol [42] NTR674 Phase III, randomized, multicenter Imatinib 400 mg qd 55 NA 46(17–65) 29 44 22 / / /
Imatinib 400 mg qd + Ara-C 54 NA 45(23–65) 37 39 20 / / /
Hughes 2014 Blood [43] NCT
00760877
Phase III, randomized, open-label, multicenter (ENESTcmr) Nilotinib 400 mg bid 104 68.3 46(23–82) / / / / / /
Imatinib 400 mg qd 103 63.1 52(19–76) / / / / / /
O’Brien (2) 2014 Blood [44, 45] / Phase III, randomized, multinational, multicenter (SPIRIT2) Dasatinib 100 mg qd 407 61.0 53(18–89) / / / / / /
Imatinib 400 mg qd 407 60.0 53(18–87) / / / / / /
Deininger 2014 Br J Hematol [46] NCT
00070499
Phase II, randomized Imatinib 800 mg qd 73 64.0 52(19–82) / / / 21 30 49
Imatinib 400 mg qd 72 63.0 50(23–80) / / / 21 30 49
Hjorth-Hansen 2015 Eu J Hematol [47] NCT
00852566
Phase II, randomized multicenter (NordCML006) Dasatinib 100 mg qd 22 32.0 53(29–71) 32 45 23 / / /
Imatinib 400 mg qd 24 63.0 58(38–78) 49 34 17 / / /
Wang 2015 Blood [48] NCT
01275196
Phase III, randomized, multicenter Nilotinib 300 mg bid 134 68.0 41(18–76) 51 33 16 / / /
Imatinib 400 mg qd 133 61.0 39(19–74) 52 32 16 / / /
Kwak 2015 Blood [49] NCT
01511289
Phase III, randomized, open-label, multicenter (RERISE) Radotinib 300 mg bid 79 66.0 45(20–75) 27 48 25 / / /
Radotinib 400 mg bid 81 58.0 43(18–84) 27 48 25 / / /
Imatinib 400 mg qd 81 64.0 45(18–83) 27 48 37 / / /
Lipton 2016 Lancet Oncol [50] NCT
01650805
Phase III, randomized, open-label, multicenter Ponatinib 45 mg qd 155 63.0 55(18–89) 41 41 17 / / /
Imatinib 400 mg qd 152 61.0 52(18–86) 41 44 15 / / /
Cortes (3) 2016 Lancet Haematol [51] NCT
00802841
Phase III, randomized, multicenter (LASOR) Nilotinib 400 mg bid 96 56.0 46(32–46) / / / / / /
Imatinib 600 mg qd 95 61.0 44(33–56) / / / / / /
Hehlmann (2) 2017 Leukemia [52, 53] NCT
00055874
Randomized, open-label, multinational, multicenter Imatinib 400 mg qd 400 61.0 53(16–88) 36 40 25 / / /
Imatinib 400 mg qd + IFN-α 430 59.0 53(16–83) 39 39 22 / / /
Imatinib 400 mg qd + Ara-C 158 63.0 52(18–79) 39 34 27 / / /
Imatinib 400 mg qd after IFN-α 128 63.0 53(18–87) 40 45 15 / / /
Imatinib 800 mg qd 420 59.0 51(18–85) 37 37 27 / / /
Cortes (4) 2018 J Clin Oncol [54] NCT
02130557
Phase III, randomized, open-label, multicenter Bosutinib 400 mg qd 268 57.7 52(18–84) 38 41 201 / / /
Imatinib 400 mg qd 268 56.0 53(19–84) 40 39 21 / / /
  1. (“/” means “not available”)